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From NextGen Therapies for SJIA & MAS – 2019
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Abstract
For reasons poorly understood, and despite the availability of biological medications blocking IL-1 and IL-6 that have
markedly improved overall disease control, children with Systemic Juvenile Idiopathic Arthritis (SJIA) are now increasingly
diagnosed with life-threatening chronic complications, including hepatitis and lung disease (SJIA-LD). On October 3–4, 2019,
a two-day meeting, NextGen Therapies for Systemic Juvenile Idiopathic Arthritis (SJIA) & macrophage activation syndrome (MAS)
organized by the Systemic JIA Foundation (www.systemicjia.org/) in Washington, DC brought together scientists, clinicians,
parents and FDA representatives with the objectives (1) to integrate clinical and research findings in MAS and SJIA-LD, and
(2) to develop a shared understanding of this seemingly new pulmonary complication of SJIA. The current manuscript
summarizes discussions and conclusions of the meeting.
Keywords: Systemic juvenile idiopathic arthritis, Macrophage activation syndrome, Hemophagocytic lymphohistiocytosis,
Interferonopathy, Interstitial lung disease, Pulmonary alveolar proteinosis, Alveolar macrophages

Introduction
Systemic Juvenile Idiopathic Arthritis (SJIA), formerly Still’s
Disease, is an autoinflammatory disorder known for marked
systemic, predominantly innate immune activation [1]. The
adult counterpart is Adult Onset Still’s Disease [2]. About
15% of SJIA patients will also develop overt macrophage
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activation syndrome (MAS), an episodic hyper-inflammatory
state caused by excessive activation and expansion of macrophages with hemophagocytic properties and predominantly
CD8+ T lymphocytes [3]. It is accompanied by a surge in
IFN-γ and downstream chemokines [4], as well as strikingly
high serum levels of IL-18 [5]. MAS has been associated with
significant morbidity and mortality. For reasons poorly
understood, and despite the availability of biological medications blocking IL-1 and IL-6 that have markedly improved
overall disease control [6, 7], MAS rates have remained unchanged [8–10]. Additionally, children with SJIA and MAS
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are now increasingly diagnosed with life-threatening chronic
complications, including hepatitis and lung disease (SJIA-LD)
[11–13]. Evaluation of lung biopsies of these patients reveals
severe inflammation with features of pulmonary alveolar proteinosis (PAP), endogenous lipoid pneumonia, and fibrosis
[12, 13], all supporting that SJIA−LD is chronic and likely diagnosed late when irreversible tissue damage has already occurred. Hence, there is a profound scientific gap of how to
diagnose SJIA-LD early, elucidate risk factors, and develop
therapeutic strategies to improve its prognosis.
Conference goals and overview

As MAS and lung disease (LD) in SJIA appear to be related, on October 3–4, 2019, a two-day meeting, NextGen
Therapies for SJIA & MAS organized by the Systemic JIA
Foundation (www.systemicjia.org/) in Washington, DC
brought together scientists, clinicians, parents and FDA
representatives with the objectives (1) to integrate clinical
and research findings in MAS and SJIA-LD, and (2) to develop a shared understanding of this seemingly new pulmonary complication of SJIA. In her introduction, Dr.
Sinha, the President of the Systemic JIA Foundation, stated
that the longer-term goals of the meeting were to develop
a strategy to enable the early diagnosis of SJIA-LD and improve the management of SJIA-LD, based on the current
state of knowledge of this condition. The meeting included in depth presentations and open discussions of unpublished research findings. Dr. Sinha emphasized the
role of parental participation in this process, to ensure that
their voices are heard in planning of future observational
studies and clinical trials.
Section 1: patient perspectives
Understanding the patient experience of SJIA-LD /
moderator: Dr. Rashmi Sinha; panelists: Anna Carlson,
Regina Minerva, Emily Schumacher

Three parents of children diagnosed with SJIA-LD reported their child’s experience, highlighting the lack of
apparent pulmonary symptoms prior to diagnosis of
SJIA-LD, a common feature that may contribute to delay
in diagnosis. These testimonials provided crucial detail
and context for the natural history of SJIA-LD, and are
consistent with the pictures offered by three recent publications [12–14]. All three patients have had a rather resistant systemic component of the disease with recurrent
MAS, and as a result, have been exposed to multiple
medications including several biologics. The parents emphasized the need for relatively safe therapies that could
be initiated preventively when a child shows early signs
of MAS and/or the lung disease, instead of the highly
immunosuppressive treatment regimens that are typically used for full-blown MAS.
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Patient story - Anna Carlson

Ms. Carlson’s daughter was diagnosed with SJIA in November 2016, at the age of 1 year. She was started on
corticosteroids and canakinumab. Within 2 months, her
parents started noticing a dry hacking cough and “pneumonia” like symptoms that were unresponsive to antibiotics. Her fevers returned and canakinumab dose was
increased. In May 2017, a high-resolution chest computer tomography (HRCT) was obtained and the child
was diagnosed with interstitial lung disease (ILD). Overnight pulse oximetry revealed significant hypoxia (desaturation episodes down to the 40s). She was admitted to
the hospital, and within a few days the lung disease progressed to respiratory failure requiring admission to an
Intensive Care Unit (ICU). During this 100 day “big sick”
(as Ms. Carlson terms this event) her child required 13
days of Extra-Corporeal Membrane Oxygenation
(ECMO). After being weaned from ECMO, she developed a severe case of MAS with ferritin rapidly increasing to 280,000 ng/mL, and 10-week treatment with
etoposide was initiated.
A tracheostomy tube was placed due to continuous
need for ventilator and oxygen supplementation, as well
as G-tube to prevent aspiration. After 2 months of being
bed-ridden, her child required extensive physical, occupational and speech therapy to relearn the most basic of
activities. In August 2018, about a year after “the big
sick”, a lung biopsy revealed PAP. Noticeably, her child
did not develop clubbing until 1 year after the start of
her lung symptoms.
For the past year, Ms. Carlson’s child’s SJIA has been
mostly controlled (with normal labs and no rash or
fever), but the lung disease persists, and is easily exacerbated by infections, which typically prompt ICU readmissions with increasing needs for supplemental oxygen
(up to 20 l per minute) and more robust ventilator support. The side effects of her immunosuppressive regimen
have led to profound neutropenia, with absolute neutrophil counts falling to zero. A JAK-inhibitor was recently
started, and the family is hopeful that the combination
of biologics, JAK inhibitor and antibiotic prophylaxis will
help her child.
Ms. Carlson emphasized the need for better medication options to control the progression of SJIA-LD, and
to manage the delicate balance between adequate immunosuppression and the patient’s ability to fight infections. She is concerned that there are few available
options for treating SJIA-LD, and that her daughter has
tried most of those medications. She did not know what
they would try next if her daughter’s disease persisted.
Following the NextGen conference, Ms. Carlson’s
child has experienced new lung symptoms, such as frequent blood in sputum, significant increase in mucus
production.
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Patient story - Emily Schumacher

Ms. Schumacher described the story of her daughter,
who is now 6 years old. She first developed signs of
SJIA-like disease in 2015 with fevers and rash, initially
thought to be a viral illness. Initial treatment of her SJIA
included subcutaneous injections of tocilizumab. Since
there was no response, tocilizumab was replaced with
high dose daily anakinra injections. Cyclosporine and
methotrexate were added few weeks later. SJIA remained
active, and anakinra was next replaced with canakinumab without improvement of SJIA symptoms.
Despite all the efforts to avoid corticosteroids, oral
prednisolone was started in July 2016, and the child continued to remain chronically steroid dependent 3 years
later. In the same year, intravenous tocilizumab was initiated with the hope that infusions would work better
then subcutaneous injections. Unfortunately, the child
had an unusual reaction during her 3rd infusion, with
tachycardia, and tachypnea requiring additional oxygen
supplementation. After this event, tocilizumab was permanently discontinued.
The family was referred for a second opinion to Cincinnati Children’s Hospital, where they were informed
that the child was in the state of mild subclinical MAS.
The doctors also noticed mildly increased respiratory
rate and subtle clubbing of the fingers, but her HRCT
showed only subtle abnormalities. A repeat HRCT 1 year
later, however, suggested significantly worsening pulmonary disease; a lung biopsy performed about 1 month
later confirmed PAP and SJIA-LD. At that time, mycophenolate was added to her drug regimen.
Prior to being diagnosed with SJIA-LD, Ms. Schumacher’s child never had any apparent lung symptoms, and
her peripheral pulse oximetry had been consistently normal. Apart from the clubbed fingers and mildly increased respiratory rate with physical activity, the child
certainly lacked overt signs of lung disease at the time of
SJIA-LD diagnosis.
With the combination of SJIA, subclinical MAS, and
SJIA-LD, her child has been on up to 10 daily medications including oral corticosteroids, high dose anakinra,
cyclosporine, methotrexate, and abatacept. In May 2018,
overt MAS prompted another hospital admission, likely
triggered by cytomegalovirus (CMV). Emily was having
difficulty clearing the CMV virus and required continuous antiviral treatment in addition to MAS therapy. For
the last year, each attempt to decrease either corticosteroids or antivirals, was followed by early signs of subclinical MAS.
Ms. Schumacher is worried that the current cocktail of
medications which seemingly cannot be weaned, is not a
sustainable therapeutic strategy. She strongly feels that
daily corticosteroids for long periods of time are not an
appropriate treatment for children. Her child is not
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growing and recently developed a vertebral compression
fracture. Her rheumatologist is constantly struggling to
balance immunosuppression to keep the disease at bay
with giving the child the ability to fight off infections.
Overall, Ms. Schumacher is concerned that options are
running out to control her child’s disease. She would like
better treatment choices than steroids and currently
available biologics, since those fail to control her child’s
disease.
After NextGen conference, Ms. Schumacher’s daughter was switched from cyclosporine to tacrolimus. That
helped for a few weeks, but now again she is having frequent fevers and her laboratory test results keep raising
concerns for subclinical MAS (e.g., low platelet count).
Her team would like to start tofacitinib but have not
been able to get insurance approval thus far.
Patient story - Regina Minerva

Ms. Minerva’s daughter was diagnosed with SJIA in July
2017, at 13 months of age, and started on prednisolone
and anakinra. As prednisolone was tapered, SJIA signs
and symptoms returned with laboratory tests showing
low levels of systemic inflammation. In April 2018, when
her inflammatory markers rose further, she was seen by
hematologist / oncologist, who ruled out malignancy,
but noted that her blood cell counts were suggestive of
“low grade MAS”.
In May 2018, Ms. Minerva started noticing that her
child’s fingertips and toes were red and sore (Fig. 1). By
September 2018, she noticed enlargement of some toes.
Looking at the postings within SJIA Parents Network,
she learnt of other children who had similar finger and
toe enlargement, and were subsequently diagnosed with
lung disease. In meantime, her medical team ruled out
pulmonary hypertension with an ECHO. In January
2019, however her chest X-rays were abnormal. In May
2019, she was diagnosed with interstitial lung disease
based on typical HRCT findings.
In May–June 2019, her child’s laboratory evaluations
showed what her doctors described as “smoldering
MAS”; while the trends in some symptoms and lab test
results were suggestive of partial MAS, the child did not
have the features of “overt MAS”. On June 22, however,
the child woke up with high fever and was immediately
evaluated in the emergency room where lab tests revealed full-blown MAS with ferritin of 31,000 ng/mL.
In spite of several doses of intravenous (IV) pulse corticosteroids and cyclosporine, her child’s MAS markers
kept on worsening. Increasing the dose of anakinra to
10 mg/kg/day did not reverse the trend. Ms. Minerva
posted about her child’s MAS in the SJIA Parents Network, and learned about the emapalumab clinical trial at
Cincinnati Children’s. She was then connected to the
doctors running the clinical trial.
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available to keep her child’s disease under control. She
believes that the only medicine that brought her child’s
MAS under control, empalumab, is only available as a
rescue medication (via a clinical trial), and not for ongoing or prophylactic usage.
Discussion about patient stories

Fig. 1 Clubbing in the fingers (with permission of Ms. Minerva)

In the meantime, her child’s MAS markers continued to
worsen, her oxygenation started falling, and they were
transferred to the ICU. Ms. Minerva and her husband requested participation in the trial. On June 28th, they were
transferred to Cincinnati, and given the first dose of emapalumab as part of NCT03311854, when ferritin was at
75,000 ng/mL. After the first infusion, her fevers resolved,
oxygenation returned to normal, and ferritin came down
to 50,000 ng/mL. She resumed eating and drinking. By the
third infusion, her ferritin came down to 7000 ng/mL, and
she was returning to her normal self.
At the time of the workshop, Ms. Minerva’s child was
3 months past her emapalumab treatment. Her labs were
normal with the exception of mildly increased LDH. Her
breathing was normal, and the most recent HRCT
showed improvement from May 2019. The girl was having the energy of a child with normal health. She
remained on all the medications for SJIA, though her
doctors were slowly tapering steroids. Regina was hopeful that her child would continue to do well, but she was
also concerned about the return of inflammation, especially the MAS and lung symptoms. She emphasized the
need for therapies that could help when a child first
shows early signs of MAS and lung disease, instead of
ones that can only be used when the child is in full
blown MAS.
Post NextGen conference, Ms. Minerva’s child continued to feel well and had normal labs. More recently, she
had a flare triggered by a viral illness with laboratory test
results pointing to subclinical MAS (platelets fell, and
ferritin went up to 6000 ng/mL). The dose of anakinra
was increased, and a pulse corticosteroids was administered to bring the flare under control. Ms. Minerva is
concerned that there are no good additional options

Both parents and clinicians agreed that there was a subset of children with SJIA whom clinicians should watch
more closely for the development of SJIA-LD, including
those with SJIA onset under age 2 years, with predominantly systemic features and limited arthritis, recurrent or
“smoldering” MAS, anaphylaxis-like reaction to a biologic medication, and highly elevated serum IL-18 levels
[12–14]. The parents strongly felt that for these SJIA patients, clinicians should have a low threshold for HRCT
evaluation.
The group felt that as a general rule, children with SJIA
under the age of 6 years who fall into this high risk group,
should have a baseline chest radiograph, and overnight
pulse oximetry; for the patients older than 6 years, pulmonary function testing as well as regular screening with
a 6 min walk should also be performed. In the presence of
any abnormalities in the above-listed tests, further imaging
with HRCT of the chest is recommended. Chest CT
should also be obtained if any additional features typical
of SJIA-LD are present (e.g., growth failure, tachypnea,
chronic non-productive cough, periungual erythema or
swelling, digital clubbing as well any acute pulmonary decompensation). Episodes of routine pulmonary conditions
with an abnormal chest radiograph should be followed up
to ensure that the abnormal findings resolve. Parents and
caregivers expressed the need for low radiation imaging
options for initial and ongoing evaluation of SJIA-LD.
Section 2: mechanistic insights into SJIA-LD
Report from Goldbach-Mansky & Canna labs / Dr. Raphaela
Goldbach-Mansky

Dr. Goldbach-Mansky, whose recent research interests
have been focused on monogenic interferonopathies,
measured IFN-scores in 66 consecutive patients with no
clear genetic diagnosis seen at the NIAID for presumed
undifferentiated autoinflammatory diseases. Among 41
patients with elevated IFN scores, 8 had recurrent episodes of MAS, features of pulmonary alveolar proteinosis (PAP) and extremely high serum IL-18 levels, and
thus, were named “IL-18 PAP-MAS” [14]. This subgroup
of patients, whose presentation included erythematous
clubbing and eventual PAP, included some described
above as SJIA-LD. These 8 patients had intermediately
high IFN scores, which were lower than the values observed in the monogenic interferonopathies such as
CANDLE. A ratio of interferon-response genes that can
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be induced by IFNα/β and IFNγ over those induced by
IFNα/β alone was higher in the IL-18 PAP-MAS patients
compared to the autoinflammatory Type-I interferonopathies CANDLE and SAVI, suggesting a combined role
of the Type-I IFNs (IFN-α and IFN-β) as well as Type II
interferon (IFN-γ) in the immune dysregulation. Within
the “IL-18 PAP-MAS” group, the IFN score correlated
weakly with total IL-18 levels suggesting that IFN gene
expression may further be co-regulated by IL-18. No
unique genetic defect was identified for this group of patients, but cytokine analyses in the blood revealed elevation of hematopoietic stem cell factors that was
associated with high serum IL-18 levels, a phenomenon
described in other patients with high serum IL-18 levels
(including the monogenic MAS predisposing disease
NLRC4-MAS), but not in patients with other IL-1 mediated autoinflammatory diseases [15] or the autoinflammatory Type-I interferonopathies, CANDLE and SAVI.
Elevated hematopoietic stem cell factors may indicate a
distinct downstream pathway that can contribute to
macrophage dysfunction in patients with high IL-18
levels [14]. The presence of free IL-18 in the bronchoalveolar lavage (BAL) fluid of patients with IL-18 PAPMAS raises the question whether stem cell factors, when
induced locally in the bronchial tree and or the lung,
may also contribute to the alveolar macrophage dysfunction and be an additional target for treatment.
Report from Grom & Schulert labs / Dr. Alexei Grom

Drs. Grom and Schulert reported on the Cincinnati cohort of patient with SJIA-LD that have many overlapping
features with the “IL-18 PAP-MAS” described by Dr.
Goldbach-Mansky. The vast majority of SJIA-LD patients had recurrent episodes of MAS, features of PAP
and extremely high serum IL-18 levels [12]. SJIA-LD patients lacked genetic, serologic, or functional evidence of
GM-CSF pathway dysfunction typical of familial or autoimmune PAP where dysfunction of alveolar macrophages leads typically to accumulation of pulmonary
surfactant in alveolar space [16]. SJIA-LD lungs had a
striking prominence of alveolar septal expansion by an
interstitial lymphocytic infiltrate and fibrosis with remodeling that are usually absent in familial or autoimmune PAP. Additionally, in SJIA-ILD (but not familial
or autoimmune PAP) the bronchoalveolar lavage (BAL)
fluid contained elevated levels of IL-18 and IFN-induced
chemokines CXCL-9 and -10. Transcriptional profiling
of SJIA-ILD lung tissue identified upregulated T-cell and
interferon activation networks, again suggesting pathophysiologic overlap with the cohort described by Dr.
Goldbach-Mansky.
Due to significant overlap in genes induced by type I
and type II interferons, the relative involvement of these
cytokines in SJIA-LD still needs to be clarified. However,
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the fact that most patients with SJIA-LD have had MAS,
suggests that the inflammatory cytokine milieu that
drives macrophage dysfunction in MAS may also promote dysfunction of alveolar macrophages. Interferon
gamma (IFN-γ) has been increasingly recognized as a
pivotal cytokine in MAS [4], and therefore, the IFNinduced signature in the lung biopsies is most likely
driven by IFN-γ. Consistent with this hypothesis, mice
with T-cell restricted overexpression of T-bet driving
IFN-γ production demonstrated both dysfunction of
bone marrow macrophages, resulting in erythrophagocytosis and alveolar macrophage dysfunction with development of PAP-like lung pathology [17]. Combined, these
observations suggest that targeting IFN-induced pathways might be a therapeutic option in SJIA-LD. In contrast, given the presence of alveolar septal expansion and
the likely different underlying defect leading to the accumulation of pulmonary proteinosis in SJIA-LD, traditional treatments for primary PAP such as whole lung
lavage may not be helpful in SJIA-LD patients.
Alveolar macrophage dysfunction in lung disease: Dr.
Stewart Levine

Since lung macrophages have a clear role in the pathogenesis of SJIA-LD, Dr. Levine presented new pulmonary insights into a range of lung disorders with
macrophage dysfunction that might be informative regarding the pathobiology of SJIA-LD. So far, hereditary
or autoimmune PAP have served as the main reference
point for the alveolar lung disease in SJIA, so it was
helpful to start considering other lung diseases which
also have macrophage dysfunction. The three other diseases that he presented were Lipoid Pneumonia,
Asthma, and High-fat Diet-induced Lung Disease (see
Table 1).
Lipoid pneumonia was identified as part of the
spectrum of SJIA-LD in two recent publications [12, 13].
Lipoid pneumonia is an uncommon disease characterized by the accumulation of intra-alveolar lipids and
lipid-laden macrophages [18]. The typical etiology of
Table 1 Lung Diseases Caused by Macrophage Dysfunction
Disease

Macrophage Dysfunction

Pulmonary Alveolar
Proteinosis (PAP)

Surfactant accumulation in alveolar
macrophages and alveoli

Lipoid Pneumonia

Lipid-laden macrophages and accumulation
of intra-alveolar lipids

House Dust Mite + Virusinduced Asthma

Up-regulated apolipoprotein E (APOE)
production by alveolar macrophages with
resultant NLRP3 inflammasome activation
and secretion of mature IL-1β

High-fat Diet-induced
Lung Disease

Lipid-laden macrophages, increased lung
cholesterol content, increased proinflammatory cytokines (interferon-γ, TNF
and IL-6).
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lipoid pneumonia is due to the exogenous inhalation or
aspiration of oils or lipids into the lung, but endogenous
etiologies have also been described in patients with PAP,
Niemann-Pick disease (which is a lipid-storage disorder)
and undifferentiated connective tissue disease, as well as
a consequence of airway obstruction due to tumor.
Dr. Levine reviewed that alveolar macrophage function
could be pro-inflammatory in the setting of asthma.
Under normal conditions, alveolar macrophages primarily receive inhibitory signals which are anti-inflammatory
[19]. However, in disease states, activating signals can
override the normal inhibitory mechanisms that suppress macrophage activation. Dr. Levine’s lab has shown
that this can occur in asthma where pro-inflammatory
stimuli, such as house dust mite (HDM) antigen, can induce apolipoprotein E (APOE) production by alveolar
macrophages [20]. When APOE levels are sufficiently
high, such as when a viral infection is superimposed
upon HDM exposure, APOE can function as a proinflammatory danger signal that activates the NLRP3
inflammasome and induces secretion of mature IL-1β by
alveolar macrophages.
Dr. Levine next reviewed murine models of high-fat
diet induced lung macrophage dysfunction that may
have some similarities with macrophage dysfunction in
SJIA-LD. When mice are fed a high-fat diet, this induces
systemic inflammation and oxidative stress that causes
pathological lung remodeling manifested by emphysema,
sarcoid-like granulomatous inflammation, pulmonary fibrosis, and pulmonary hypertension [21]. Lungs from
mice fed a high-fat diet show increased numbers of pulmonary macrophages, increased lung cholesterol content, lipid-laden macrophages, and increases in
bronchoalveolar fluid cytokines (IFN-γ, TNF and IL-6).
Thus, in the appropriate setting, such as high-fat dietinduced systemic inflammation or house dust mite plus
viral infection, alveolar macrophages can be converted
from an anti-inflammatory cell that maintains normal
pulmonary homeostasis into a pro-inflammatory cell
that may promote disease pathogenesis. The concept of
the alveolar macrophage as a target cell that amplifies
inflammation may also be relevant for SJIA-LD.
Dr. Levine reviewed that alveolar macrophage populations in the lung are heterogeneous and can be
broadly divided into two categories. Tissue-resident
alveolar macrophages (TR-AMs) are the most abundant immune cell in the lung under normal conditions [22, 23]. TR-AMs represent a long-lived, selfrenewing population that are derived from the fetal
yolk sac and liver and function to maintain normal
pulmonary homeostasis and gas exchange. In contrast,
monocyte-derived alveolar macrophages (Mo-AMs)
are recruited into the lung from the blood in the setting of inflammation where they have cytotoxic,
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antimicrobial, and pro-fibrotic functions. Thus, MoAMs augment inflammation, which suggests a role for
these cells in SJIA-LD. Once inflammation resolves
and homeostasis is restored, Mo-AMs undergo apoptosis or differentiate into cells that phenotypically resemble TR-AMs. Single cell RNA-seq experiments in
a mouse model of LPS-induced inflammation have
identified two distinct populations of TR-AMs and
three populations of MO-AMs. Thus, single cell
RNA-seq might represent a method to drill deeper
into macrophage pathobiology in SJIA-LD.

Section 3: current approaches to management and
outcomes of SJIA-LD
Learnings from Cincinnati SJIA-LD patient cohort / Dr.
Grant Schulert

Dr. Schulert provided a short update on the cohort of
SJIA-LD patients evaluated at Cincinnati Children’s.
They have now evaluated 27 children with SJIA-LD
including 9 patients since submission of their initial
manuscript [12]. Of those 27 patients, only 1 (4%)
has died, which is in marked contrast to the larger,
multisite cohorts [11, 13]. The reasons for this improved outcome are not known, but may include earlier diagnosis, and introduction of T-cell targeted
therapies, such as mycophenolate mofetil and tacrolimus, as well as azathioprine and anti-inflammatory
and prophylactic antibiotic. The treatment for SJIALD may also adapt some of the new approaches used
in the treatment for MAS rather than SJIA, specifically treatments that can target T cell activation and
interferon pathways including JAK inhibition.
Dr. Schulert also noted that their practice has been
continuing anti-cytokine biologics to gain control of
MAS and inflammation of active SJIA as an essential
step in treatment of SJIA-LD. Controlling MAS in these
patients is utterly important but often challenging. Dr.
Schulert also noted there are several patients in the Cincinnati SJIA-LD cohort who have markedly improved
and even resolved features of lung disease over several
years. Indeed, these patients were able to achieve full
control of their underlying SJIA and MAS with continued biologics along with therapies noted above.
There was also some discussion regarding possible role
of biologic medications and geographic distribution of
patients. Biologics are used now near universally
throughout North American and Europe but SJIA-LD
cases seem much more prevalent in the US, and even
possible regional clusters within the US. This would be
consistent with other environmental factors or triggers
playing a role, which needs to be considered and investigated moving forward.
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Section 4: potentially targetable pathways and candidate
therapeutics for SJIA-LD
Review of biomarkers; IL18 as a biomarker and a target /
Dr. Scott Canna

Dr. Canna presented a serum proteomics study performed in collaboration with Cincinnati and Stanford
aimed at the identification of novel lung disease biomarkers that was eventually presented at American College of Rheumatology (ACR) 2019 Annual Meeting [24].
IL-18 has long been a biomarker of interest in patients
with SJIA and MAS. IL-18 is uniformly and dramatically
elevated in patients with active MAS. It is likewise
chronically elevated, regardless of disease activity, in a
few rare monogenic situations including gain-offunction mutations in NLRC4 [15], XIAP-deficiency
[25], and c-terminal mutations in CDC42 regardless of
disease activity [26, 27]. It is more variably elevated in
active and inactive SJIA, with some patients’ levels as
high as in active MAS and other patients’ level nearnormal. Dr. Canna presented ongoing work related to
IL-18 as a biomarker of MAS risk [5, 28–31], a host susceptibility factor for the development of MAS, and it’s
peculiar elevation in SJIA-LD patients out of proportion
to such patients’ degree of MAS activity. The latter point
was supported by an unpublished multi-center collaborative serum proteomics study presented at the ACR
2019 Annual Meeting [24].
This study also suggested novel pathways in MAS,
biomarkers of lung inflammation/damage, and potentially a role for type 2 immune responses in SJIA-LD.
In addition, one SJIA-LD patient has shown a promising response to compassionate-use treatment with an
IL-18 blocking strategy [32], and a clinical trial of IL18 blockade in NLRC4 and XIAP patients is ongoing
(NCT03113760). Corroborating the recent work of
Schulert et al. [12], Dr. Canna’s unpublished observations suggest elevation of total and free IL-18 in BAL
fluid of SJIA-LD patients, but not in various controls.
IL-18 is produced constitutively by some macrophages, but also by intestinal epithelial cells, keratinocytes, and bronchial epithelial cells. It is not known
where the high IL-18 in SJIA and MAS derives from.
Functionally, IL-18 is best known as an amplifier of
Type 1 immune responses and specifically of IFN-γ
production. The connections between IFN-γ and
MAS, and potentially lung disease, were discussed by
Dr. de Benedetti. While, IL-18 has been shown to
amplify immune responses other than IFN-γ, including anti-bacterial (Type 17) or allergic (Type 2) responses, depending on the immune context, some of
the transcriptional evidence from Schulert et al. [12]
suggests that Type 1 inflammatory responses/IFN-γ
may be an important part of SJIA-LD.
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An overview of selective JAK-inhibitors and relevance for
SJIA-LD / Dr. Massimo Gadina

Given some pathophysiologic overlap between SJIA-LD
and interferonopathies, a group of auto-inflammatory
diseases where targeting JAK-STAT signaling pathways
often produces a good clinical response, Dr. Gadina presented an overview of this therapeutic strategy. JAKs are
phosphotransferases that bind the intracellular domains
of cytokine receptors and transmit signals to activate immune responses [33]. Cytokines that signal via JAKs includes many interleukins, interferons, colony stimulating
factors and hormone-like cytokines (such as erythropoietin and growth hormone). The receptors for these cytokines signal via various combinations of four JAKs
(JAK1, JAK2, JAK3 and TYK2). First-generation JAK
inhibitors, such as tofacitinib and baricitinib block more
than one JAK, and thereby can inhibit a large number of
cytokines and growth factors; these and other pan-JAK
inhibitors are being investigated as therapeutic agents
for a wide variety of autoimmune diseases. Based on
some similarities between SJIA-LD and interferonopathies such as SAVI, JAK-inhibitors (tofacitinib) have
been used in a few children with SJIA-LD, with mild improvement in some of them. More data and experience
are needed to understand the efficacy and safety of this
class of medications in the treatment of SJIA-LD.
Dr. Gadina also presented an overview of newer, more
selective JAK-inhibitors as well as their safety and effectiveness in other diseases. Few next generation JAK inhibitors have already reached the market or are in an
advanced status of development. Nonetheless, it appears
that selective JAK inhibitors do not necessarily reduce
the risk of infection compared with first generation JAK
inhibitors. Common side effects observed include infection, anemia, neutropenia, lymphopenia and hyperlipidemia. It has become apparent that, in children,
tofacitinib increases the risk of chickenpox which correlates with the observed increased rates on Herpes zoster
flares in adults.
There was also discussion of whether broader JAKinhibitors might interfere with the erythropoietin and
growth hormone signaling pathways leading to anemia
and growth delays. Dr. Gadina highlighted, however, that
in patients with the autoinflammatory Type-1 interferonopathy, CANDLE, treatment with baricitinib resulted
in improved disease control and concomitantly patients
resumed relatively normal growth. This suggests that
better disease and inflammation control might be predominant over the potential effects of the drug on
growth hormone signaling. As many cytokine receptors
and growth receptors use JAK-STATs for signaling, including the growth hormone receptor, concerns regarding off target effects of JAK inhibition in children remain
till more data become available.
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The possibility to combine a JAK inhibitor with a biologic was discussed and compared with a combined
therapy of a JAK inhibitor with methotrexate or corticosteroids. So far, the data are limited to few anecdotal
cases and larger studies are needed to assess the safety
of a combination therapy. Finally, at least in the case of
baricitinib, the drug half-life is weight based and shorter
in children than in adults, and an increase in frequency
of administration and in doses may be needed to achieve
therapeutic efficacy.
Is targeting IFNγ-induced pathways likely to be effective
in SJIA-LD? / Dr. Fabrizio De Benedetti

Dr. De Benedetti reviewed evidence supporting targeting
IFNγ-related pathways in SJIA-LD. A growing body of
evidence, albeit indirect, supports the hypothesis that
IFNγ may be a pathogenic mediator of SJIA-LD: 1) the
vast majority of SJIA-LD patients have a history of MAS,
often recurrent [11–13], and IFNγ is implicated as the
pivotal cytokine in MAS; 2) in the 12 months preceding
onset of the lung disease, patients with SJIA-LD have rising ferritin and levels are higher than those of SJIA patient without lung disease [13]; 3) a prominent IFNinduced signature is present in lung biopsies of SJIA-LD
patients with overexpression of genes specifically upregulated by IFNγ [12]; and 4) mice with t-bet CD4 restricted overexpression develop an inflammatory PAP,
characterized by a CD4 infiltrate (similar to that present
in SJIA-LD lungs) and by a prominent IFN-γ signature
[17]. Finally, in these mice abnormal differentiation of
tissue macrophages was demonstrated suggesting a shift
towards M1 macrophage and subsequent inability to
clear surfactant proteins, again pointing to a derangement of macrophage differentiation as a potential
mechanism.
Altogether, these observations suggest that therapeutic
neutralization of IFN-γ should be considered as a potential therapeutic approach in SJIA-LD. Emapalumab is an
anti-IFNγ antibody that has been approved by the FDA
for patients with primary hemophagocytic lymphohistiocytosis (HLH). The preliminary results of the ongoing
phase II trial of emapalumab in MAS/SJIA showed
complete response in all of the 9 patients enrolled, all of
whom had previously failed conventional therapies [34].
New drug discovery: computational approaches to drug
repurposing by reversing gene expression in SJIA-LD /
Drs. Grant Schulert & Alex Pickering

Alex Pickering from Harvard Medical School described
an innovative computational approach to understanding
SJIA-LD and also identifying repurposed drugs. This
project is the result of a collaboration between the
Cincinnati Children’s, Harvard University and the Systemic JIA Foundation. It relies on an approach called
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connectivity mapping on RNA-Seq data. Connectivity
mapping uses a gene expression profile from patients to
search for drugs and genetic manipulations that have either similar or opposing effects on gene expression.
Drugs that oppose the gene expression changes observed
in the patients are predicted therapeutics. Genetic manipulations that either oppose or mimic these gene expression changes suggest a role of the manipulated gene
in the disease process.
Early results appear promising and highlight the opportunity to identify additional therapeutic targets and
approved drugs that can reverse the disease signature.
Out of ~ 7000 genetic manipulations, those that correlate most strongly with gene expression in whole lung
samples from patients with SJIA-LD either upregulate
IFN-γ or NF-kB signaling. IFN-γ signaling in lung NK,
T, endothelial, and macrophage cells from a SJIA-LD patient also appeared to be upregulated. As compared to
the same cell types from an uninvolved biopsy (Fig. 2),
IFITM1, a type I and II interferon induced transmembrane protein that inhibits viral cytoplasmic entry (doi:
https://doi.org/10.1074/jbc. M115.657346,) and PSMB10,
a IFNγ-regulated component of the immunoproteosome,
were among the top most significantly upregulated genes
(Fig. 3).
Section 5: overlapping clinical phenotypes that may share
common disease mechanisms with SJIA-LD
Patient experience of MAS-liver patients / moderator:
Rashmi Sinha; panelists: Zulayka Martinez, Katie Pierce

Patients with lung disease are not the only subgroup of
SJIA patients with MAS and predominant organ-specific
involvement. Another small, but distinct subgroup of patients from the SJIA Parents Network is patients with
MAS and liver involvement. Two parents of children diagnosed with SJIA, MAS, and persistent liver issues reported their child’s experience specifically highlighting
the connection between recurrent MAS and persistent
liver disease.
Patient story - Zulayka Martinez

Ms. Martinez recounted the story of her daughter, who is
now 6 years old. At the age of 4 years, they first started noticing recurrent rashes. Two months later, in April 2018,
she started getting fevers as well. The laboratory test pattern pointed to SJIA, but her rashes were atypical, and she
had marked generalized enlargement of her lymph nodes.
After a long investigative workup which included several
MRIs, X-rays, HRCT scans, ultrasound studies, and a bone
marrow biopsy, other diseases were ruled out, and she was
diagnosed with SJIA. Because of prominent MAS features,
the child received multiple pulses of IV corticosteroids
and improved. She was also started on anakinra and,
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Fig. 2 UMAP dimensionality reduction after integrating an affected and unaffected lung sample from a patient with SJIA-LD

initially, had a good response to it. In November 2018, she
was unwell again. While general laboratory test results
were suggestive of only mild systemic inflammation, the
liver function tests were persistently elevated and kept rising (AST/ALT above 200’s unit/L).
In January 2019, she was admitted with rashes and generalized pains. Her medical team decided to replace anakinra with tocilizumab. During the first infusion, she
developed a strange pruritic rash, and complained of

throat pain that compromised her ability to swallow. She
finally improved, mainly in response to IV corticosteroids.
Anakinra was added back to the tocilizumab. She
responded well to the addition of anakinra and was better
for a few days, but then the inflammatory activity started
rising again. During the second infusion of toclizumab,
she started to gag, and her blood pressure dropped. The
infusion was stopped immediately, and the treatment with
tocilizumab was permanently discontinued.

Fig. 3 NK- and T-cell clusters split by sample (TEST = affected, CTRL = unaffected) and colored by pre-integration expression of IFITM1 and
PSMB10. Analyses performed with Seurat version 3.0
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By the beginning of February 2019, her liver function
tests were rising again (AST 425 unit/L, ALT 512 unit/
L), and her serum total IL-18 level reached 364,588 pg/
mL (up from 183,292 pg/mL 2 months earlier). By the
end of February 2019, she was admitted for increasing
liver enzymes (AST 981 unit/L, ALT 704 unit/L) associated with moderate hyperferritinemia (ferritin 465 ng/
ml), which could not be controlled even with IV pulse
corticosteroids. Hepatology was consulted and a liver biopsy was obtained. The liver biopsy results were inconclusive, but did not show signs characteristic of drug
injury. Her team felt comfortable increasing the dose of
anakinra, but within 4 days, her liver enzymes further increased (AST - 4070 unit/L, ALT - 4557 unit/L). Her
ferritin was 540 ng/ml, and LDH reached 8170 unit/L.
Anakinra was discontinued, and her SJIA symptoms
returned: rash, fevers, intense body and throat pain.
She got some relief with IV corticosteroids and was
next started on canakinumab. Over the next few weeks,
her inflammatory markers started improving. The liver
markers mildly improved, but still remained highly elevated (LDH 2575 unit/L, AST 1206 unit/L, ALT 2079
unit/L), and total IL18 was at 245,581 pg/mL. Regularly
scheduled pulse steroids were used to keep the liver disease under some degree of control. In the meantime,
additional staining of the liver biopsy with anti-CD163
and anti-CD8 antibodies revealed histopathologic features suggestive of MAS.
Liver enzymes started rising again and in the fall of
2019, tacrolimus was added to her treatment regimen
with some improvement: within a week, LDH dropped
from 4020 to 1753 unit/L; AST from 1034 to 241 unit/L,
and ALT from 1601 to 499 unit/L.
Ms. Martinez noted that her daughter’s symptoms
were primarily fevers, rash, pain, sore throat and elevated liver function tests. She did not have true arthritis.
Her team has found serum total IL-18 to be very useful
in tracking her disease activity, and it is now being monitored monthly. LDH seems to be another useful marker.
She also noted that the only medication that works for
her daughter are IV corticosteroids, and she now receives
an infusion at least weekly, and often more frequently
when the child is in a flare. She is tired of the many side
effects that her child is experiencing including marked
growth retardation, weight gain, and mood changes. She
would like to have more medication options suitable for
cases of SJIA, MAS and associated liver disease.
Since the NextGen conference, Ms. Martinez’s daughter
has had a few mild flares. However, since adding tacrolimus, her daughter’s lab test abnormalities have improved
and overall she has been doing better. The frequency of
canakinumab injections has been increased. Oral corticosteroids are being slowly tapered, but IV corticosteroid
pulses are still administered every 2 weeks.
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Patient story - Kate & Jonathan Pierce

Mr. and Mrs. Pierce’s 2 years old daughter was diagnosed with SJIA at the age of 8 months after several
weeks of recurrent fevers and rash. She was initially suspected to have atypical Kawasaki disease, but she did not
respond to IVIG, and several ECHO studies were normal. After further testing, the diagnosis was changed to
Systemic JIA. Her disease was initially controlled with
anakinra and prednisone, but after 3 months of the
treatment, with corticosteroid taper, her fevers and rash
returned. In spite of switching biologics to canakinumab
and increasing her prednisone dose, her fevers persisted
and inflammatory markers continued to rise.
In October 2018, she developed MAS. She recovered
quickly with tocilizumab and IV corticosteroids, but 10
days later, the MAS recurred for a second time. This
MAS episode was more difficult to treat and was characterized by increasing liver inflammation in spite of improvement in all other MAS markers. During this
hospitalization she was found to have cytomegalovirus
(CMV) infection which was thought to explain her persistent liver inflammation. The inflammation was eventually controlled and her steroids were slowly tapered.
She received five infusions of tocilizumab, before she
developed an anaphylactic type reaction to the drug.
After this reaction, tocilizumab was replaced with canakinumab, and the dose of corticosteroids was increased
again followed by a very slow taper.
Mrs. Pierce noted that her daughter’s typical SJIA
symptoms were fever, rash, and enlarged spleen and
liver. She did not have true arthritis. Remarkably, her
total IL-18 levels were always very elevated, particularly
during or right after MAS. After the last MAS episode,
total her IL-18 was at 361,000 pg/mL.
By the beginning of 2019, once she completed her
steroid taper, her LFTs were again elevated, though the
rest of lab test results were mostly normal (ferritin in
the 30s ng/mL, still low hemoglobin, with WBC count
of 8.0 K, and platelet count at 200 K). CMV was no longer detectable in her blood.
A liver biopsy was performed in April 2019. Though
results of the biopsy were inconclusive, there were
“punched out lesions of hepatocellular necrosis” which
were felt to be related to the inflammation from SJIA or
MAS. There were no signs of active CMV infection in
the liver.
For the past year, she has struggled with persistent inflammation causing nightly fevers and elevated inflammatory markers, including liver enzymes. She has been
on corticosteroids for most of this time, causing significant growth delay.
Since this summer, her team has been trying different
drug combinations to effectively control her inflammation. They first tried adding anakinra to the
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canakinumab for a month. When that did not help, they
next tried adding tacrolimus to her regimen. For about a
month, her labs completely normalized, but then the inflammatory markers started rising again and fevers
returned.
Her team did a renewed search for drugs to control
her inflammation, and considered a range of options
including Rilonacept, thalidomide and JAK-inhibitors.
She was recently started on tofacitinib with the hope
that this will result in better control of her inflammation and help wean corticosteroids. However, her
daughter has been flaring again recently. Her team is
continuing with tofacitinib, but also started the initial
evaluation for possible hematopoietic stem cell
transplantation.
Mr. and Mrs. Pierce are interested in other drug options to control her daughter’s inflammation, as steroids
have severe side effects when used long term, and none
of the biologic medications can control her child’s disease, especially the MAS and liver inflammation.
Pathology in recurrent MAS with liver involvement / Drs.
Alexei Grom & Fabrizio DeBenedetti

It has been recognized that a subset of patients who do
not meet full criteria for SJIA or overt MAS, may have
recurrent or “smoldering/incomplete MAS”. A proportion of these patients have predominantly liver involvement. Wouters, et al. previously described typical
histopathologic findings in these patients: sinusoidal inflammatory infiltrate is a prominent feature and consists
both of increased number of CD8+ T lymphocytes and
highly activated Kupffer cells with some of them exhibiting hemophagocytic activity [35]. The CD8 immunostaining in these patients typically identifies large
numbers of CD8 positive lymphocytes both in the portal
infiltrates and in the sinusoidal infiltrates. The CD163
immunostaining marks large numbers of activated macrophages with plump contours both in the portal areas
and in the sinusoids. Immunostaining for cytokines
identifies CD8+ T cells as the main producers of large
amounts of IFN-γ.
Consistent with this study, three patients with predominant liver involvement recently evaluated by Dr. De
Benedetti (2 of whom fully met the ILAR criteria for
SJIA), had similar histopathologic pattern, including
large numbers of CD68+ macrophages. Their liver biopsies showed highly increased levels of mRNA for IFNγinduced genes, while other classical pro-inflammatory
cytokines were not markedly increased, including IL-18,
IL-6 and TNF-α. Type I IFN induced gene expression
was also roughly normal. These observations suggest
that IFN-γ and IFN-induced pathways might be an attractive therapeutic target in this patient population as
well [36].
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“Persistent partial MAS” as the common link between
SJIA-LD and MAS-liver patients / group discussion

The discussion was then focused on “persistent partial”
or “smoldering”” MAS as the common link between
both sets of patients.
Parent observations

Several parents of both SJIA-LD and SJIA-Liver patients
described that their children were in a state of what was
best described as “smoldering MAS” for prolonged periods of time. They would have low-grade fever, some
rash, and fatigue. Lab tests would show some features of
MAS, but not full-blown MAS. Clinicians who had
treated such patients agreed with this observation and
emphasized that treating such patients with existing
medications was challenging.
Since most children with SJIA-LD have a low level of
persistent inflammatory activity and some laboratory abnormalities typical of MAS without meeting the full Ravelli’s 2016 MAS criteria [37], the point was made that a
substantial proportion of children with SJIA-LD might
have “smoldering” MAS. The concept of “smoldering”
MAS has not been formalized, and since this is a potential
target for any future studies and clinical trials, the group
sought to generate a preliminary definition, criteria and
possible an alternative term to describe this state. The
group discussed several terms for this clinical state, and
while no consensus was achieved, a majority of participants endorsed the phrase “persistent partial MAS”.
The group identified the potential characteristics to
define “persistent partial MAS”: in a patient with active
SJIA and persistent inflammation (provided that infection or other causes have been ruled out), there should
be newly worsening or persistently abnormal values for
at least 6 weeks (with inability to taper medications because of worsening values) indicating:





liver abnormalities
disorder of hematopoiesis
coagulopathy
highly elevated serum IL-18 with modestly elevated
CXCL9

The presence of all 4 of these should support the diagnosis of “persistent partial MAS”. Numeric laboratory
values for the three components of the definition still
needs to be defined in the future.
Section 6: planning for future clinical trials
Alternative designs for a trial for recurrent MAS with
organ (lung / liver) involvement

Dr. Rashmi Sinha then summarized the patient perspective regarding the need for new treatments for patients
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with MAS and lung / liver involvement. The entire
group recognized that patients who have recurrent MAS
associated with SJIA, SJIA-LD or MAS with Liver Disease not only have high mortality, but also have diseaseand medication-related morbidities that slowly accumulate, affecting all aspects of the child’s health-related
quality of life. With input from representatives from the
FDA, possible approaches to the design and implementation of a clinical trial for this population were
discussed. Potential therapeutic strategies included
neutralization of IFN-γ with emapalumab, JAKinhibitors, and/or IL-18 inhibitors.
The group felt that the study design should address
the current unmet need, take into consideration patient
reported outcomes, and should also meet the regulatory
requirements to gain approval for this indication. Appropriate outcome measures should be considered including
patient reported outcome (PRO) measures as well as
meeting (as yet unidentified) “MAS remission” criteria.
There was an agreement that the ability to taper corticosteroids, as well as other concomitant medications,
should be avoided as a primary outcome measure, but
must be used as secondary measures, given the clinical
relevance of the comorbidities associated with the multiple chronic therapies of these children.
Developing patient-reported outcomes measures for
clinical / session moderated by: Dr. Hermine Brunner

Dr. Brunner reviewed currently available PRO measures
of health-related quality of life that have been validated
and including those used in the clinical trial of tocilizumab in SJIA [6]. These PRO measures, however,
were mainly aimed at the assessment of the effects of
the arthritic and, to a lesser degree, the systemic components of the disease. Therefore, the current PRO measures are unlikely to be sensitive enough to fully capture
“persistent-partial” SJIA and/or SJIA-LD, and future
work is needed to develop such a measurement tool.
Summary of parent observations

Parents shared what signs they use to judge whether
their child is doing better or worse. They described both
systemic and lung specific symptoms, but also reported
a complex interaction between the lung and systemic
symptoms of the underlying SJIA (e.g., a child might be
affected due to shortness of breath (due to lung symptoms), and/or tired and achy (due to systemic symptoms). Potential outcome measures suggested by the
parents are listed in Table 2.
The parents then discussed potential “lung-relevant”
PRO candidate items that, from their prospective, could
distinguish between worsening lung disease and worsening systemic component of SJIA (Table 3).
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Table 2 Potential Parent Reported Outcome Measures - For
Systemic & Lung Disease
Lack of energy / decreased physical activity/being sluggish
Behaviors like sitting on the couch and playing with iPad, or just sitting
quietly
Fatigue - reporting tiredness after minor exertion
Disturbed sleep at night
Not wanting to get out of bed
Grumpy behavior: being annoyed without reason, with siblings and
parents
Less smiling and laughing behavior
Reduced exploratory behavior / reduced sense of curiosity
Decreased interest in play
Lack of appetite
Cough
Labored breathing
Breathlessness with every day-life activities (i.e., climbing stairs)
Decreased ability to run around
Increased respiratory rate
O2 requirement (for patients who use oxygen supplementation)

For further refinement, the list generated will be (1) disseminated among a larger group of parents through the Systemic JIA Foundation network, and (2) discussed with
experts to explore whether the Patient-Reported Outcomes
Measurement Information System (PROMIS; www.healthmeasures.net) could be used to design a PRO measure to be
used in trials of medications to treat SJIA-LD.
Measuring and tracking lung disease progression: options
& challenges, Dr. Grant Schulert

Dr. Schulert reported on his work with Dr. Yukiko Kimura
to establish validated criteria to measure and track lung progression through the CARRA Registry network. He presented and discussed components of this measure including
a lung specific global assessment (SJIA-LD Severity Score),
and physician lung global assessment (PLGA). Potential specific items could include oxygen requirement, cough, exercise
intolerance, therapy intensity, and the degree of the redness
of the digits as well as the % of the involved area of the lungs
on HRCT. Drs. Schulert and Kimura hope to establish a cohort through the CARRA Registry to collect a small number
of such measures prospectively to track disease evolution,
along with obtaining biosamples through the CARRA Biobanks in the US and Canada.
Section 7: conclusions & future steps
Plans for a new international refractory SJIA project:
ReSyst

The meeting recognized that there are subgroups of refractory SJIA patients (including SJIA-LD, liver-
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Table 3 Lung-relevant PRO Candidate Items
Symptoms
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Table 4 Provisional Classification Criteria for Refractory SJIA

Lung Disease - Specific

SJIA - Specific

Flushing

Fever

Cough

Rash

Labored breathing

Chest pain

Pruritis

Joint pain

Failure to respond to IL-1 AND IL-6 blocking biologics (failure = inability
to resolve arthritis, systemic symptoms, or liver dysfunction, or being
steroid dependent)
OR
≥2 episodes of MAS in a 2 year period
OR
Development of SJIA-LD

Joints stiffness
Fatigue
Low energy
Decreased appetite
Decreased physical activity
Feeling sad
Lack of engagement/participation
Lack of curiosity
Decreased interest in play
Signs

Heart rate

Fever

Respiratory rate

Rash

Oxygen requirement

Joint swelling

Growth failure

Hepatomegaly

Erythematous clubbing

Splenomegaly
Lymphadenopathy
Poor linear growth

predominant MAS, and resistant/destructive arthritis,
among others) who need to be identified quickly and
treated appropriately. Identifying the appropriate treatments will mean addressing the challenges of 1) small
patient numbers, 2) high patient complexity/severity,
and 3) the lack of approved treatment options. While
the rest of the meeting focused on the efforts to understand and treat SJIA-LD, there is also a clear need for a
parallel effort to recognize and understand refractory
SJIA in general.
The meeting closed with a discussion between clinicians, researchers, and parents regarding the efforts to
create an international consortium focused on understanding of treatment-resistant SJIA (ReSyst). This effort
includes groups from the US, Canada, the Netherlands,
and Italy. Such an effort would leverage several existing
networks including Pediatric Rheumatology European
Society (PReS), the European Reference Centers, Childhood Arthritis Research Alliance (CARRA), and UCAN
CAN-DU. As a first step, the group agreed upon a
provisional definition of refractory SJIA shown in
Table 4.
More discussions will follow regarding funding and
the logistics of collaborations needed between the organizations to collect clinical data and biospecimens on
these patients.

Conclusions
In conclusion, the mortality rate of children with
SJIA-LD is high, and effective targeted treatments remain elusive. This underscores the urgent need to
diagnose SJIA-LD early, elucidate risk factors, and develop therapeutic strategies to improve its prognosis.
Environmental and genetic factors are likely to contribute to the development of the lung disease, but
increasing evidence suggests that SJIA-LD may be
caused by alveolar macrophage dysfunction with contributions from the SJIA/MAS inflammatory milieu
and possibly, from increasing use of the IL-1 and IL6 blocking therapies. Potential novel therapeutic strategies include targeting (1) IFN-γ with the monoclonal
anti-IFNγ antibody emapalumab; (2) the IFNγinduced pathways with Janus kinase inhibitors, and
(3) IL-18 with the IL18-blocking agent tadekinig alfa
or other agents. Any potential clinical trial design in
Refractory SJIA, or SJIA-LD more specifically, should
address the current unmet need, should take into
consideration patient reported outcomes, and should
aim for regulatory approval for this indication. Importantly, the perspective of patients and families
must be frequently and seriously considered at all
phases of such trials.
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